Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pregabalin for painful diabetic peripheral neuropathy


Painful symptoms of diabetic peripheral neuropathy have been shown to be improved by treatment with the antiepileptic drug pregabalin. Freeman et al. performed a meta-analysis of 7 randomized, placebo-controlled trials that evaluated the efficacy and safety of pregabalin treatment for painful diabetic peripheral neuropathy. The trials were consistent in their inclusion and exclusion criteria, but involved a variety of doses (150, 300 and 600 mg/day) and dosing intervals (2 or 3 times per day). Pregabalin was found to be effective for painful diabetic peripheral neuropathy at all doses and intervals reviewed. Additionally, higher pregabalin doses resulted in faster reduction in pain scores and sleep interference when compared with lower doses and placebo. The greatest and apparently most rapid pain reduction was observed in patients receiving pregabalin 600 mg/day, divided into 2 or 3 doses. On the basis of these findings, pregabalin can be a useful therapy for painful diabetic neuropathy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. Dyck PJ et al. (1993) The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 43: 817–824

    CAS  PubMed  Google Scholar 

  2. Boulton AJ et al. (2005) Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28: 956–962

    Article  PubMed  Google Scholar 

  3. Dooley DJ et al. (2007) Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 28: 75–82

    Article  CAS  PubMed  Google Scholar 

  4. Freeman R et al. (2008) Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 31: 1448–1454

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rogers LC et al. (2004) Treatment of painful diabetic neuropathy: a review of the most efficacious pharmacologic treatments. Practical Diabetes Int 21: 301–306

    Article  Google Scholar 

  6. Galer BS et al. (2000) Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 47: 123–128

    Article  CAS  PubMed  Google Scholar 

  7. Sullivan SD et al. (2002) Health state preference assessment in diabetic peripheral neuropathy. Pharmacoeconomics 20: 1079–1089

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to David G Armstrong.

Ethics declarations

Competing interests

Lee C Rogers has declared an association with the following company: Pfizer (speakers bureau). David G Armstrong declared no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rogers, L., Armstrong, D. Pregabalin for painful diabetic peripheral neuropathy. Nat Rev Endocrinol 5, 14–15 (2009).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing